These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 31275667)

  • 21. Head-to-head comparison of two SGLT-2 inhibitors on AKI outcomes in a rat ischemia-reperfusion model.
    Chu C; Delić D; Alber J; Feger M; Xiong Y; Luo T; Hasan AA; Zeng S; Gaballa MMS; Chen X; Yin L; Klein T; Elitok S; Krämer BK; Föller M; Hocher B
    Biomed Pharmacother; 2022 Sep; 153():113357. PubMed ID: 35792391
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Canagliflozin-induced pancreatitis: a rare side effect of a new drug.
    Chowdhary M; Kabbani AA; Chhabra A
    Ther Clin Risk Manag; 2015; 11():991-4. PubMed ID: 26170677
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A population-based cohort defined risk of hyperkalemia after initiating SGLT-2 inhibitors, GLP1 receptor agonists or DPP-4 inhibitors to patients with chronic kidney disease and type 2 diabetes.
    Fu EL; Mastrorilli J; Bykov K; Wexler DJ; Cervone A; Lin KJ; Patorno E; Paik JM
    Kidney Int; 2024 Mar; 105(3):618-628. PubMed ID: 38101515
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparative safety of different sodium-glucose transporter 2 inhibitors in patients with type 2 diabetes: a systematic review and network meta-analysis of randomized controlled trials.
    Li CX; Liu LY; Zhang CX; Geng XH; Gu SM; Wang YQ; Liu H; Xie Q; Liang S
    Front Endocrinol (Lausanne); 2023; 14():1238399. PubMed ID: 37701900
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Physicians' Considerations and Practice Recommendations Regarding the Use of Sodium-Glucose Cotransporter-2 Inhibitors.
    Jabbour SA; Ibrahim NE; Argyropoulos CP
    J Clin Med; 2022 Oct; 11(20):. PubMed ID: 36294370
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Sodium-glucose cotransporter 2 inhibitors: an evidence-based practice approach to their use in the natural history of type 2 diabetes.
    Schwartz SS; Ahmed I
    Curr Med Res Opin; 2016 May; 32(5):907-19. PubMed ID: 26854518
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Renal hemosiderosis presenting with acute kidney Injury and macroscopic hematuria in Immunoglobulin A nephropathy: a case report.
    Taguchi S; Hidaka S; Yanai M; Ishioka K; Matsui K; Mochida Y; Moriya H; Ohtake T; Kobayashi S
    BMC Nephrol; 2021 Apr; 22(1):132. PubMed ID: 33858363
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Renal and Cardiovascular Effects of Sodium Glucose Co-Transporter 2 Inhibitors in Patients with Type 2 Diabetes and Chronic Kidney Disease: Perspectives on the Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation Trial Results.
    Weir MR; McCullough PA; Buse JB; Anderson J
    Am J Nephrol; 2020; 51(4):276-288. PubMed ID: 32172239
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Targeted Cancer Therapies Causing Elevations in Serum Creatinine Through Tubular Secretion Inhibition: A Case Report and Review of the Literature.
    Mach T; Qi A; Bouganim N; Trinh E
    Can J Kidney Health Dis; 2022; 9():20543581221106246. PubMed ID: 35756332
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Use of Sodium-Glucose Transport Protein 2 (SGLT2) Inhibitor Remogliflozin and Possibility of Acute Kidney Injury in Type-2 Diabetes.
    Jain R; Bhavatharini N; Saravanan T; Seshiah V; Jain N
    Cureus; 2022 Dec; 14(12):e32573. PubMed ID: 36654590
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Sodium-glucose cotransporter 2 (SGLT-2) inhibitors for patients with Type 2 diabetes].
    Røder ME; Storgaard H; Rungby J; Knop FK; Vilsbøll T
    Ugeskr Laeger; 2016 Sep; 178(38):. PubMed ID: 27649712
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Spotlight on Canagliflozin 300: review of its efficacy and an indirect comparison to other SGLT-2 inhibitors and long-acting GLP-1 receptor agonists.
    Singh AK; Singh R
    Expert Rev Clin Pharmacol; 2017 Jun; 10(6):633-647. PubMed ID: 28393583
    [TBL] [Abstract][Full Text] [Related]  

  • 33. SGLT-2 receptor inhibitors for treating patients with type 2 diabetes mellitus: a systematic review and network meta-analysis.
    Shyangdan DS; Uthman OA; Waugh N
    BMJ Open; 2016 Feb; 6(2):e009417. PubMed ID: 26911584
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sodium-glucose Cotransporter-2 Inhibitors induced euglycemic diabetic ketoacidosis: A meta summary of case reports.
    Juneja D; Nasa P; Jain R; Singh O
    World J Diabetes; 2023 Aug; 14(8):1314-1322. PubMed ID: 37664476
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Use of SGLT-2 Inhibitors in Patients With Type 1 Diabetes Mellitus.
    El Hage L; Kashyap SR; Rao P
    J Prim Care Community Health; 2019; 10():2150132719895188. PubMed ID: 31894715
    [No Abstract]   [Full Text] [Related]  

  • 36. Comparative efficacy of once-weekly semaglutide versus SGLT-2 inhibitors in patients inadequately controlled with one to two oral antidiabetic drugs: a systematic literature review and network meta-analysis.
    Kanters S; Wilkinson L; Vrazic H; Sharma R; Lopes S; Popoff E; Druyts E
    BMJ Open; 2019 Jul; 9(7):e023458. PubMed ID: 31340953
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotransporter-2 Inhibitors).
    Kosiborod M; Cavender MA; Fu AZ; Wilding JP; Khunti K; Holl RW; Norhammar A; Birkeland KI; Jørgensen ME; Thuresson M; Arya N; Bodegård J; Hammar N; Fenici P;
    Circulation; 2017 Jul; 136(3):249-259. PubMed ID: 28522450
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impact of SGLT Inhibitors on Multiple Organ Defects in Diabetes.
    Asrih M; Gariani K
    Curr Diabetes Rev; 2020; 16(5):411-418. PubMed ID: 31702506
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and Safety of SGLT-2 Inhibitors for Treatment of Diabetes Mellitus among Kidney Transplant Patients: A Systematic Review and Meta-Analysis.
    Chewcharat A; Prasitlumkum N; Thongprayoon C; Bathini T; Medaura J; Vallabhajosyula S; Cheungpasitporn W
    Med Sci (Basel); 2020 Nov; 8(4):. PubMed ID: 33213078
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Demographic and Clinical Profiles of Type 2 Diabetes Mellitus Patients Initiating Canagliflozin Versus DPP-4 Inhibitors in a Large U.S. Managed Care Population.
    Grabner M; Peng X; Geremakis C; Bae J
    J Manag Care Spec Pharm; 2015 Dec; 21(12):1204-12. PubMed ID: 26679969
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.